How to Get Alprostadil (Caverject/MUSE) in Colorado

Alprostadil Prescribing Laws in Colorado

Any physician (MD or DO), nurse practitioner, or physician assistant holding an active Colorado license can prescribe alprostadil. Colorado does not impose separate restrictions on prescribing injectable erectile dysfunction medications beyond standard controlled-substance protocols, and alprostadil is not a controlled substance under either federal or Colorado schedules.

NPs in Colorado have full practice authority after 3 to 520 hours of supervised practice under Colorado Revised Statutes 12-255-112, meaning they can independently evaluate, diagnose, and prescribe alprostadil without physician co-signature. PAs may prescribe under their delegated authority agreement with a supervising physician, which in practice covers most outpatient prescriptions including alprostadil.

The prescriber must document the clinical rationale for alprostadil, typically failure of or contraindication to oral PDE5 inhibitors such as sildenafil or tadalafil. The Linet et al. 1996 trial (N=296) established that intracavernosal alprostadil produced erections sufficient for intercourse in 87% of patients across dose ranges of 2.5 to 20 mcg, a response rate that remains the benchmark cited in urologic guidelines [1]. That clinical evidence base is what makes alprostadil the standard second-line therapy for men who cannot use oral agents.

Telehealth Access Across Colorado

Colorado allows telehealth prescribing of alprostadil statewide. The state's telehealth parity law (C.R.S. 10-16-123) requires private insurers to cover telehealth-delivered services at the same rate as in-person visits, which extends to the evaluation and prescribing appointment for erectile dysfunction medications.

A telehealth visit for alprostadil typically follows this sequence: a synchronous video consultation with a licensed prescriber, review of relevant labs and medical history, dose selection, and electronic prescription sent to the patient's chosen pharmacy. Most telehealth platforms complete the initial evaluation within 24 to 48 hours of scheduling.

One clinical constraint applies. The FDA-approved labeling for Caverject requires that the first dose be administered in a medical office under clinician supervision to monitor for prolonged erection (priapism) and to teach proper injection technique [2]. Telehealth prescribers in Colorado typically coordinate this first-dose visit at a local urology office, urgent care clinic, or through a visiting nurse arrangement. After the supervised first injection, subsequent doses can be self-administered at home.

For patients in rural Colorado counties (where roughly 25% of the state's population resides across the Western Slope, Eastern Plains, and San Luis Valley), telehealth removes the geographic barrier. A patient in Montrose or Trinidad does not need to drive to Denver or Colorado Springs for an erectile dysfunction evaluation.

Required Labs Before Prescribing

Before writing an alprostadil prescription, most Colorado clinicians order a focused laboratory panel. The goal is to rule out reversible causes of erectile dysfunction and confirm that alprostadil is appropriate. A standard pre-prescribing workup includes total testosterone (drawn between 8 and 10 AM on two separate mornings), fasting glucose or HbA1c, a lipid panel, and a complete metabolic panel.

The Endocrine Society's 2018 clinical practice guideline recommends measuring testosterone in all men presenting with erectile dysfunction, since 12% to 19% of men with ED have concurrent hypogonadism that may respond to testosterone replacement alone [3]. If testosterone is below 300 ng/dL on two morning draws, the prescriber might trial testosterone therapy before or alongside alprostadil.

Thyroid-stimulating hormone (TSH) and prolactin levels are indicated when clinical suspicion points toward endocrine dysfunction. Prolactin elevation above 25 ng/mL can suppress gonadotropin-releasing hormone and cause both low testosterone and ED.

These labs can be ordered through any Colorado laboratory. Quest Diagnostics and Labcorp operate draw stations in most Front Range cities, and many telehealth platforms partner with national lab networks to offer convenient specimen collection. Patients with recent labs (within 6 to 12 months) may not need repeat testing if results are available for prescriber review.

Pharmacy Options: Brand, Generic, and Compounded Alprostadil

Colorado patients have three pharmacy pathways for filling an alprostadil prescription.

Brand-name products. Caverject (intracavernosal injection, available as Caverject Impulse in a prefilled dual-chamber syringe) and MUSE (urethral suppository) are stocked at most major retail pharmacies, including Walgreens, CVS, King Soopers (Kroger), and Walmart locations throughout Colorado. Cash prices for brand-name Caverject Impulse range from approximately $75 to $130 per single-dose syringe without insurance, and MUSE suppositories typically run $35 to $60 per unit at retail.

Generic alprostadil. Generic intracavernosal alprostadil injection is available from several manufacturers and is substantially cheaper than brand-name Caverject. Generic pricing at Colorado pharmacies often falls between $30 and $70 per vial depending on concentration and pharmacy markup.

503A compounding pharmacies. Colorado licenses 503A compounding pharmacies through the Colorado State Board of Pharmacy under C.R.S. 12-280-120. These pharmacies can prepare patient-specific alprostadil formulations, including combination intracavernosal injections (sometimes called "trimix" or "bimix") that pair alprostadil with papaverine and/or phentolamine. A compounded trimix vial typically costs $50 to $120 and provides multiple doses.

503A pharmacies in Colorado can ship compounded alprostadil within the state to the patient's address, provided the prescription specifies a patient-specific formulation. Compounded injectables require cold-chain shipping (insulated packaging with ice packs), and most Colorado compounding pharmacies ship via overnight or two-day delivery to maintain potency. Patients in the Denver metro area may also pick up directly.

The FDA's guidance on 503A compounding distinguishes patient-specific compounding (503A) from outsourcing facilities (503B) [4]. Colorado patients should verify that their compounding pharmacy holds an active Colorado Board of Pharmacy license before ordering.

Colorado Medicaid and Insurance Coverage

Colorado Medicaid (Health First Colorado) does not cover alprostadil for standard erectile dysfunction. A narrow exception exists for ED documented as secondary to type 2 diabetes with supporting clinical documentation, but in practice this exception is rarely approved.

Private insurers in Colorado, including Anthem, Cigna, Aetna, United Healthcare, and Kaiser Permanente of Colorado, vary widely in their coverage of alprostadil. Many commercial plans classify erectile dysfunction medications as non-essential or lifestyle drugs, placing them on specialty tiers with high copays or excluding them outright.

When coverage is available, prior authorization is almost always required. The documentation packet for prior authorization in Colorado typically includes:

• A chart note documenting the diagnosis of erectile dysfunction with ICD-10 code N52.01 (erectile dysfunction due to arterial insufficiency), N52.1 (erectile dysfunction due to diseases classified elsewhere), or N52.9 (male erectile dysfunction, unspecified)
• Documentation of trial and failure of at least one PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil), including dates, doses, and reason for discontinuation
• Relevant lab results (testosterone, HbA1c if diabetes is present)
• A letter of medical necessity from the prescriber

Processing times for prior authorization with Colorado insurers range from 48 hours to 14 business days. The prescriber's office handles the submission, but patients should request a copy of the determination letter for their records.

For self-pay patients, manufacturer coupons and pharmacy discount programs can reduce costs. Pfizer's patient assistance program offers Caverject at reduced cost for patients meeting income criteria (generally below 400% of the federal poverty level).

First-Dose Supervision and Injection Training

The supervised first dose is not optional. This is a distinct clinical step. The FDA label for Caverject specifies in-office titration to identify the lowest effective dose that produces an erection lasting no longer than one hour [2]. The clinician starts at 2.5 mcg for neurogenic ED (such as post-prostatectomy) or 2.5 to 5 mcg for vasculogenic ED, then increases in increments of 2.5 to 5 mcg at intervals of at least one day until a satisfactory response is achieved.

During the first-dose visit, the clinician also teaches injection technique: selecting the injection site on the lateral aspect of the penile shaft (alternating sides), using a 27- to 30-gauge needle, applying pressure post-injection, and recognizing warning signs of priapism (erection persisting beyond 4 hours requiring emergency treatment).

For MUSE, the first-dose protocol involves inserting the urethral suppository in the office and monitoring for 30 to 60 minutes. The Padma-Nathan et al. 1997 trial (N=1,511) found that 65.9% of men using MUSE achieved erections sufficient for intercourse at home after in-office titration, with the 1 to 000 mcg dose producing the highest response rate [5].

Colorado urology practices in Denver, Colorado Springs, Fort Collins, Boulder, and Grand Junction routinely perform in-office alprostadil titration. Patients using telehealth for their initial evaluation can typically schedule the titration visit within 1 to 2 weeks.

Timeline: From Evaluation to First Home Dose

The full process of obtaining alprostadil in Colorado breaks down into discrete steps.

Week 1: Initial evaluation (telehealth or in-person) and lab orders. Labs drawn and resulted, typically within 2 to 4 business days. Week 2: Prescriber reviews labs, selects initial dose, sends prescription to pharmacy. If prior authorization is needed, the clock starts here. Week 2 to 3: In-office first-dose titration visit. Week 3: Pharmacy fills the prescription (retail: same day to 2 days; compounding: 3 to 7 business days). Patient begins self-administration at home.

Without insurance delays, most Colorado patients move from first consultation to home use in 2 to 3 weeks. Prior authorization can add 1 to 2 additional weeks.

Transferring an Alprostadil Prescription to Colorado

Patients relocating to Colorado from another state can transfer an existing alprostadil prescription to a Colorado pharmacy under the state's standard prescription transfer rules. The receiving pharmacist contacts the originating pharmacy to verify the prescription details, prescriber information, and remaining refills.

Two conditions apply. The prescriber on the original prescription must be verified as holding an active license (in their home state; Colorado does not require the originating prescriber to hold a CO license for a one-time transfer). The prescription must not be expired under Colorado's prescription validity rules (one year from date of issue for non-controlled medications).

For compounded formulations, transfers are more complex because compounding prescriptions are often specific to a pharmacy's proprietary formulation ratios. Patients may need their new Colorado prescriber to write a fresh prescription specifying the desired compounding pharmacy's formulation.

Safety Monitoring and Ongoing Follow-Up

After successful titration, ongoing monitoring is straightforward. The American Urological Association's ED guideline recommends follow-up at 1 to 3 months after starting intracavernosal therapy to assess efficacy, side effects, and injection technique [6]. The most common adverse effect is penile pain at the injection site, reported in 37% of patients in the Linet et al. trial [1]. This pain is usually mild and diminishes with continued use.

Priapism (erection lasting more than 4 hours) occurs in approximately 1% to 3% of patients using intracavernosal alprostadil and constitutes a medical emergency. Colorado patients should know the location of their nearest emergency department. Penile fibrosis, reported in 3% to 8% of patients with long-term use, requires periodic clinical examination.

Patients should not exceed 3 injections per week or one injection per 24-hour period, and the maximum single dose is 40 mcg for Caverject. MUSE users should not exceed 2 applications per 24-hour period.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a principal contributor to the AUA erectile dysfunction guidelines, has stated: "Intracavernosal injection therapy remains the most effective non-surgical treatment for erectile dysfunction, with response rates exceeding those of any oral agent when properly titrated" [6].

The European Association of Urology's 2024 guidelines on male sexual dysfunction echo this position, recommending intracavernosal alprostadil as first-line injectable therapy with a Grade A evidence rating based on multiple randomized controlled trials [7].